Furthermore, given the role played by FXR in nonalcoholic fatty liver disease (NAFLD) [51], ARD is also a promising pharmacological agent against NAFLD. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.